Intravenous cyclosporine for refractory attacks of Crohn's disease (CD): Long-term follow-up of patients

Risks and benefits of biologic therapy for inflammatory bowel diseases

“…A literature search revealed three additional cases of HSTL in patients with Crohn's disease who were on azathioprine/6-mercaptopurine (duration 4-6 years), who had never been exposed to infliximab. [34][35][36] In addition, a recent metanalysis pooled data from nine selected placebo-controlled trials with infliximab and adalimumab for the treatment of rheumatoid arthritis, comprising over 5000 patients. Of these, 3493 patients had received at least one dose of an anti-TNF agent.…”

Hepatosplenic T Cell Lymphoma Associated with Infliximab Use in Young Patients Treated for Inflammatory Bowel Disease: Update

“…Seven cases associated with azathioprine use have been published; many of these reports provided little specific clinical and/or demographic data (4)(5)(6)(7)(8)(9)(10). Of the 7 cases, all developed HSTCL (5 reported gd subtype, 2 did not report a subtype) associated with azathioprine use to treat Crohn disease (CD; n ¼ 4), ulcerative colitis (UC; n ¼ 2), or UC/ hepatitis (n ¼ 1) for a duration of 4 to 17 years (mean 7.5 years).…”

Hepatosplenic T cell lymphoma in inflammatory bowel disease

“…Although six cases of HSTCL have previously been reported in patients with IBD treated with thiopurine therapy alone,20 – 25 the description of a cluster of eight cases occurring between 1998 and 2006 in patients treated with infliximab has led to an urgent requirement to understand better the relationship of anti-TNF drugs and this specific form of lymphoma (table 1). 14 Seven of the eight cases occurred in male patients and, except for one patient with ulcerative colitis, all received the drug for Crohn’s disease.…”